PubMed
Thymosin beta 4 and wound healing: a multifunctional peptide
Goldstein et al., 2010
Healing & RecoveryResearch OnlyA
TB-500
Thymosin Beta-4 Fragment
TB-500 is the active synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino acid protein naturally present in virtually all human cells and critical to actin regulation, cell migration, and tissue regeneration. Research shows TB-500 promotes angiogenesis, reduces inflammation, improves tissue flexibility, and accelerates recovery from musculoskeletal injuries. Not FDA-approved; banned from 503A compounding pharmacies.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 9
- Research grade
- A
- Experience
- 72
- Activity
- 75
Overall check-ins
Trackers & reports
Overview
About TB-500
TB-500 is the active synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino acid protein naturally present in virtually all human cells and critical to actin regulation, cell migration, and tissue regeneration. Research shows TB-500 promotes angiogenesis, reduces inflammation, improves tissue flexibility, and accelerates recovery from musculoskeletal injuries. Not FDA-approved; banned from 503A compounding pharmacies.
- Category
- Healing & Recovery
- Regulatory status
- Research Only
- Also known as
- Thymosin Beta-4 Fragment
- Self-reports
- 103
Community
What 103 users report
103 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 38% · Mixed 62% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
219
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
70
Fatigue
65
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
14
0.025–0.05 mg
1
0.1–0.2 mg
1
0.2–0.4 mg
29
0.4–0.6 mg
25
0.6–1 mg
2
1–2 mg
5
2–3 mg
72
3–5 mg
45
5+ mg
25
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 23% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 63 days · Based on 40 repeat reporters
Research
Cited research (7)
Source
PubMed
Thymosin β4 promotes angiogenesis, healing, and cardiac function
Smart et al., 2012
ClinicalTrials.gov
Thymosin beta-4 studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein et al., 2012
PubMed
Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing
Li et al., 2007
PubMed
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield et al., 2026
PubMed
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman et al., 2026
Tools
Explore more
Explore
More ways to learn about TB-500 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about TB-500?
This page summarizes 103 anonymized self-reports from PeptIQ users who track TB-500, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for TB-500?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for TB-500?
7 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is TB-500 safe to use?
This wiki does not assess safety or recommend use. TB-500 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of TB-500?
Research, primarily in animal models, suggests TB-500 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of TB-500?
TB-500 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified TB-500 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of TB-500?
The safety and effectiveness of TB-500 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on TB-500?
While there are over 200 published studies on TB-500, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source